7501-37-3

Upstream product

• 6947-81-5 4-(4-isopropylphenyl)-4-oxobutanoic acid 
• 96-48-0 4-butanolide 
• 98-82-8 Isopropylbenzene 
• 151-50-8 potassium cyanide 
• 54338-32-8 4-(4-cyclohexylphenyl)butanoic Acid 
• 855151-26-7 ethyl 4-(4-isopropylphenyl)butanoate 
• 17356-09-1 4-iodocumene 

Downstream Products

• 35338-72-8 7-isopropyl-3,4-dihydro-2H-naphthalen-1-one 
• 229339-62-2 Methyl 4-(4-isopropylphenyl)butanoate 
• 76372-19-5 3-(p-Isopropenylphenyl)propyl dimethyl carbinol 
• 2027-17-0 2-Isopropylnaphthalene 
• 7501-40-8 1-Methyl-7-isopropyl-1,2,3,4-tetrahydronaphthalin-1-ol 
• 1233389-77-9 4-(4-isopropylcyclohexyl)butanoic acid 
• 1311276-13-7 C₁₉H₂₃NO₂ 

Relevant academic research and scientific papers

NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS

The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacte

PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS

The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.

AMINO ALCOHOL COMPOUND

A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): (wherein R 1 represents a methyl group or an ethyl group, R 2 represents a methyl group or an ethyl group, and R 3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

Synthesis of 1,1,5,6-tetramethyl-and 7-isopropyl-1,1-dimethyl-1,2,3,4-tetrahydronaphthalene

4-(2,3-Dimethylphenyl)butanoic acid (4) was treated with excess of methyllithium to yield 5-(2,3-dimethylphenyl)-2-methylpentan-2-ol (6) which was cyclodehydrated using Dowex 50W-X8 resin, trifluoroacetic acid or polyphosphoric acid (PPA) to furnish 1,1,5,6-tetramethyl-1,2,3,4-tetrahydronaphthalene (1). The acid 4 was cyclized with PPA to furnish 5,6-dimethyl-3,4-dihydronaphthalen-1(2H)-one (5) which was converted into 1 by reaction with dimethylzinc and titanium tetrachloride. 4-(4-Isopropylphenyl)butanoic acid (7) on esterification followed by Grignard reaction with methylmagnesium iodide furnished 5-(4-isopropylphenyl)-2-methylpentan-2-ol (9), which was cyclodehydrated as above to yield 7-isopropyl-1,1-dimethyl-1,2,3,4-tetrahydronaphthalene (2).

Phosphonic acid compounds, their production and use

The present invention relates to a compound of the general formula (I): STR1 wherein ring A is a benzene ring that may be substituted; Y is a divalent group as a constituent member of ring B forming a 5- to 8-membered ring; Q1 is a group of the formula --X--P(O)(OR1)(OR2) wherein X is a bond or a divalent group; R1 and R2, identical or different, are hydrogen or a lower alkyl, or may be combined together to form a ring; Q2 is hydrogen, a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; and the group of the formula --CON(Q1)(Q2) is connected to the a- or b-position carbon atom, or a salt thereof, which is useful as prophylactic and therapeutic agents of various metabolic bone diseases such as osteoporosis.